UNSPSC 51172328: Sugammadex

This classification denotes a protective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 361LPM2T56. European Medicines Agency schedules Sugammadex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26695. Sugammadex generally arises in the molecular formula C72H112O48S8. The term SUGAMMADEX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.) Most nations schedule sugammadex under HS 29329985 and SITC 51569.

UNSPSC 51172328 Sugammadex, a Commodity code, does not map cleanly to recent state and local procurement activity. The three recent opportunities posted under or near this code—offender drug testing services (Collin County), a therapeutic pharmacy initiative RFI (Texas HHS), and generic multi-source pharmaceuticals (MMCAP)—address specimen collection, pharmacy benefit program design, and bulk pharmaceutical procurement respectively. None solicits sugammadex, a neuromuscular blocking agent reversal medication, as a line item or as part of a defined pharmaceutical supply contract. The mismatch between the code designation and the actual scope of work suggests that state and local agencies are not currently using this code to procure sugammadex in meaningful volume or that the opportunities indexed under it reflect broader pharmaceutical or testing categories rather than this specific drug product.

The recent activity does show pharmaceutical and testing procurement spanning county community-supervision departments, state health commissions, and multi-state cooperative purchasing vehicles across Texas and Minnesota. Collin County's RFP for offender drug testing (due July 23, 2026, estimated value $600,000) emphasizes laboratory certification and multi-site specimen handling rather than reversal agents. Texas HHS's RFI on direct-to-manufacturer prescriptions and MMCAP's generic pharmaceuticals RFP (due March 26, 2026) indicate broader state-level interest in pharmaceutical supply chains and cost management but do not reference anesthesia-related products. Without recent opportunities specifically naming sugammadex procurement, the code warrants a watch posture pending clearer demand signals from state anesthesiology programs, surgical centers, or hospital systems that might use it as a direct-buy category.